Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more
Zentalis Pharmaceuticals Llc (ZNTL) - Net Assets
Latest net assets as of September 2025: $252.87 Million USD
Based on the latest financial reports, Zentalis Pharmaceuticals Llc (ZNTL) has net assets worth $252.87 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($327.25 Million) and total liabilities ($74.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $252.87 Million |
| % of Total Assets | 77.27% |
| Annual Growth Rate | 47.82% |
| 5-Year Change | 1.14% |
| 10-Year Change | N/A |
| Growth Volatility | 141.94 |
Zentalis Pharmaceuticals Llc - Net Assets Trend (2018–2024)
This chart illustrates how Zentalis Pharmaceuticals Llc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zentalis Pharmaceuticals Llc (2018–2024)
The table below shows the annual net assets of Zentalis Pharmaceuticals Llc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $337.19 Million | -22.91% |
| 2023-12-31 | $437.39 Million | +0.78% |
| 2022-12-31 | $434.02 Million | +19.08% |
| 2021-12-31 | $364.48 Million | +9.33% |
| 2020-12-31 | $333.38 Million | +387.24% |
| 2019-12-31 | $68.42 Million | +111.79% |
| 2018-12-31 | $32.31 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zentalis Pharmaceuticals Llc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 101706500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $71.00K | 0.02% |
| Other Comprehensive Income | $558.00K | 0.17% |
| Other Components | $1.39 Billion | 412.52% |
| Total Equity | $337.19 Million | 100.00% |
Zentalis Pharmaceuticals Llc Competitors by Market Cap
The table below lists competitors of Zentalis Pharmaceuticals Llc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wuxi Xinan Technology Co. Ltd. A
SHE:301170
|
$129.48 Million |
|
Hansa Biopharma AB
ST:HNSA
|
$129.55 Million |
|
EKF Diagnostics Holdings plc
PINK:EKDHF
|
$129.58 Million |
|
Theratechnologies Inc.
NASDAQ:THTX
|
$129.60 Million |
|
CVC Brasil Operadora e Agencia
SA:CVCB3
|
$129.40 Million |
|
HUA YU LIEN Development Co Ltd
TW:1436
|
$129.39 Million |
|
Cape Industries Ltd
KQ:064820
|
$129.32 Million |
|
Digital Imaging Technology INC
KQ:110990
|
$129.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zentalis Pharmaceuticals Llc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 437,284,000 to 337,186,000, a change of -100,098,000 (-22.9%).
- Net loss of 165,839,000 reduced equity.
- New share issuances of 349,000 increased equity.
- Other comprehensive income decreased equity by 1,636,001.
- Other factors increased equity by 67,028,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-165.84 Million | -49.18% |
| Share Issuances | $349.00K | +0.1% |
| Other Comprehensive Income | $-1.64 Million | -0.49% |
| Other Changes | $67.03 Million | +19.88% |
| Total Change | $- | -22.89% |
Book Value vs Market Value Analysis
This analysis compares Zentalis Pharmaceuticals Llc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.58x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.99x to 0.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $1.37 | $2.73 | x |
| 2019-12-31 | $1.72 | $2.73 | x |
| 2020-12-31 | $7.52 | $2.73 | x |
| 2021-12-31 | $8.53 | $2.73 | x |
| 2022-12-31 | $8.21 | $2.73 | x |
| 2023-12-31 | $6.69 | $2.73 | x |
| 2024-12-31 | $4.74 | $2.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zentalis Pharmaceuticals Llc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -245.96%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.28x
- Recent ROE (-49.18%) is above the historical average (-58.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -85.05% | -150478.57% | 0.00x | 1.66x | $-23.54 Million |
| 2019 | -74.13% | 0.00% | 0.00x | 1.43x | $-51.82 Million |
| 2020 | -38.19% | 0.00% | 0.00x | 1.18x | $-148.70 Million |
| 2021 | -43.61% | 0.00% | 0.00x | 1.30x | $-195.12 Million |
| 2022 | -54.59% | 0.00% | 0.00x | 1.28x | $-280.19 Million |
| 2023 | -66.82% | 0.00% | 0.00x | 1.29x | $-335.92 Million |
| 2024 | -49.18% | -245.96% | 0.16x | 1.28x | $-199.56 Million |
Industry Comparison
This section compares Zentalis Pharmaceuticals Llc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zentalis Pharmaceuticals Llc (ZNTL) | $252.87 Million | -85.05% | 0.29x | $129.42 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |